ATH 33.3% 0.4¢ alterity therapeutics limited

Orphan designation benefits ?, page-21

  1. 1,560 Posts.
    lightbulb Created with Sketch. 2
    I agree that there is little use to copy abstracts of in vitro testing. But interesting info can sometimes be identified even that early in the research process, and the Chinese scientists and their peers thought that it was important enough to have it published in a scientific journal. And some of you were kind of excited.

    Being honest as I am, I must tell you that I disagree with your claim of the Chinese research being 10 -15 years behind PBT2. Honestly, I don't think that in my opinion either of the two MOA's will gain much headway toward eventual approval for commercialization. Time will tell - possibly in 10 to 15 years.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
0.001(33.3%)
Mkt cap ! $21.28M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $9.838K 3.277M

Buyers (Bids)

No. Vol. Price($)
75 100044686 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 157644647 64
View Market Depth
Last trade - 16.10pm 12/11/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.